Clinical Trials Logo

Filter by:
NCT ID: NCT03093974 Completed - Clinical trials for Non Cystic Fibrosis Bronchiectasis

Efficacy and Safety of Inhaled CMS in Bronchiectasis Subjects With Chronic P. Aeruginosa Infection. (PROMIS-I)

PROMIS-I
Start date: June 6, 2017
Phase: Phase 3
Study type: Interventional

The objective of the trial was to investigate the effect of the use of inhaled CMS, administered b.i.d. via a specific nebuliser for 12 months, compared to placebo in subjects with NCFB chronically infected with P. aeruginosa on the annualised frequency of pulmonary exacerbations.

NCT ID: NCT03093818 Completed - Clinical trials for Adverse Drug Reaction

PREemptive Pharmacogenomic Testing for Preventing Adverse Drug REactions

PREPARE
Start date: March 20, 2017
Phase: N/A
Study type: Interventional

PREPARE is an international, prospective, multi-center, open, randomized, cross-over implementation study assessing the impact of pre-emptive pharmacogenomic testing, of a panel of actionable pharmacogenomic variants, on adverse event incidence. Additional outcomes include, healthcare expenditure, process indicators for implementation and provider adoption of pharmacogenomics.

NCT ID: NCT03093675 Completed - Uterine Diseases Clinical Trials

Robotic Assisted Surgery for Treatment of Gynecological Diseases: Pilot Study

Start date: October 23, 2013
Phase: N/A
Study type: Interventional

This is a prospective, single-center clinical trial. One hundred and fifty patients affected by adnexal and uterine diseases will be recruited to undergo treatment with robotic assisted laparoscopic procedures using the innovative TELELAP ALF-X Endoscopic Robotic Surgical System with the primary objective of assessing the feasibility, efficacy and safety of this approach.

NCT ID: NCT03093480 Completed - Clinical trials for Hemophilia A With Inhibitors

A Study to Evaluate Efficacy of rFVIIIFc for Immune Tolerance Induction (ITI) in Severe Hemophilia A Participants With Inhibitors Undergoing the First ITI Treatment (verITI-8 Study)

Start date: December 8, 2017
Phase: Phase 4
Study type: Interventional

The primary purpose of this study was to describe the time to tolerization (i.e., ITI success) with rFVIIIFc in participants within a maximum of 48 weeks (12 months) of ITI treatment.

NCT ID: NCT03091569 Completed - Clinical trials for Relapsing-Remitting Multiple Sclerosis

Effects of Vitamin K on Redness Associated With Injection Site Reactions in Participants Treated With Plegridy

VITALITY
Start date: March 10, 2017
Phase: Phase 4
Study type: Interventional

The primary objective of the study is to investigate whether topical Vitamin K application reduces the grade of erythema in comparison with a vehicle cream (placebo) through physicians' assessment and participant self-assessment. The secondary objectives of this study are to evaluate in this study population: effects of Vitamin K in reducing the burning sensation and local pain; effects of Vitamin K in reducing the erythema diameter; and the evaluation of participants' satisfaction related to the injection treatment.

NCT ID: NCT03091127 Completed - Multiple Myeloma Clinical Trials

Real-world Use of Carfilzomib Among Multiple Myeloma Patients in Europe

Start date: March 14, 2017
Phase:
Study type: Observational

With the recent addition of carfilzomib as a treatment option for multiple myeloma, no data is available yet on how the drug is being used outside of the clinical trial setting. This study will therefore provide essential data to demonstrate the real world utilization of carfilzomib in routine clinical practice, including dosage, administration schedule, regimen, duration of treatment and reason for discontinuation in Europe.

NCT ID: NCT03090360 Completed - Healthy Clinical Trials

Growth of Infants Fed a New Term Infant Formula

Start date: February 21, 2017
Phase: N/A
Study type: Interventional

To evaluate the growth of healthy term infants fed an experimental infant formula with a prebiotic, a commercial control infant formula with a probiotic, but without a prebiotic and human breast milk

NCT ID: NCT03089944 Completed - Clinical trials for Hepatitis C Virus (HCV)

A Study of Glecaprevir (GLE)/Pibrentasvir (PIB) in Treatment-Naive Adults With Chronic Hepatitis C Virus (HCV) Genotype 1-6 Infection and Compensated Cirrhosis

EXPEDITION-8
Start date: April 28, 2017
Phase: Phase 3
Study type: Interventional

A Phase 3b, single arm, open-label, multicenter study in treatment naïve adults with chronic HCV infection and compensated cirrhosis to assess the safety of 8 weeks of treatment with glecaprevir/pibrentasvir and to demonstrate the efficacy of the sustained virologic response 12 weeks post dosing (SVR12) rates of 8 weeks of treatment with glecaprevir/pibrentasvir compared to the historical SVR12 rates of 12 weeks of treatment with glecaprevir/pibrentasvir.

NCT ID: NCT03089281 Completed - Heart Failure Clinical Trials

Strategic Management to Optimize Response To Cardiac Resynchronization Therapy

SMART CRT
Start date: August 1, 2017
Phase: N/A
Study type: Interventional

The primary objective is to evaluate the benefit of the SmartDelayâ„¢ algorithm in patients with a prolonged RV-LV interval.

NCT ID: NCT03088813 Completed - Clinical trials for Small Cell Lung Cancer

Study of Irinotecan Liposome Injection (ONIVYDE®) in Patients With Small Cell Lung Cancer

RESILIENT
Start date: April 25, 2018
Phase: Phase 3
Study type: Interventional

A randomized, open label phase 3 study of irinotecan liposome injection (ONIVYDE®) versus topotecan in patients with small cell lung cancer who have progressed on or after platinum-based first-line therapy The study was conducted in two parts: 1. Dose determination of irinotecan liposome injection 2. A randomized, efficacy study of irinotecan liposome injection versus topotecan